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‘Flu’ and structure-based drug design
Rebecca C Wade
The threat of a catastrophic outbreak of influenza is ever
present. Vaccines are only partially effective and the two
compounds, amantidine and rimantidine, used clinically
against influenza A cause side-effects and rapid viral
resistance. Recent advances bring hope that specific and
potent drugs against influenza may soon be available in
the clinic. These compounds were designed to inhibit
influenza neuraminidase (NA), one of the viral coat
glycoproteins, using the crystal structure of NA which was
first published in 1983. In this review, the application of
structure-based drug design approaches to the design of
anti-influenza agents targeted at NA and haemagglutinin
(HA), the other viral surface glycoprotein, is discussed.
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The report [1] earlier this year of an orally bioavailable anti-
neuraminidase agent, GS4104, entering clinical trials means
that the day when anti-influenza tablets are readily avail-
able may not be too far off. The influenza virus’ rapid rate
of antigenic variation is the reason that vaccines are only
modestly effective, and each year bouts of influenza cause
many deaths (influenza is one of the ten most common
causes of death in the USA), much suffering and many days
of work missed: reasons enough for the development of a
good drug. Every so often the virus undergoes a major anti-
genic transformation resulting in a pandemic strain, such as
the strain which killed more than 20 million people in
1918–1919. A pandemic can strike human and other popula-
tions, such as seal, horse or fowl, at any time. Efficient
prevention of disaster requires a simply administered drug
that is effective against all types of influenza with minimal
side-effects and viral resistance. In this review, the steps
followed towards the development of candidate drugs that
may fulfil this role are charted. A crucial breakthrough in
this process was the determination of the crystal structure of
influenza NA [2] and its exploitation in structure-based
drug design (SBDD). Thus, the ways in which SBDD has
aided the design of antineuraminidase agents is examined,
and the design of these compounds is compared with that
of haemagglutinin inhibitors.
Three decades of antineuraminidase inhibitor discovery
The systematic search for antineuraminidase inhibitors
started in the 1960s and the main steps in their develop-
ment are outlined in Figure 1 (for detailed reviews see
[3,4]). NA destroys cell receptors for the virus by cleaving
the sialyl moiety, to which HA binds, from cell surface gly-
coconjugates and releasing sialic acid (Neu5Ac). The role
of NA is not completely understood [5], but it is thought
to facilitate the liberation of progeny virions from the cell
surface, thereby preventing virus aggregation. NA may
also assist the virus in penetrating mucosal secretions. The
drug design goal, therefore, has been to develop potent
NA inhibitors, first by random screening, then by mecha-
nistic design of transition state analogues, and most
recently by SBDD (Figure 2).
Pre-1983 and the NA structure determination
Random screening did not produce potent inhibitors of
NA [6]. The classical mechanistic route to enzyme
inhibitor design, namely designing a possible transition
state analogue, resulted in a promising lead compound, 2-
deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2en),
with an ~103-fold greater binding affinity than the product,
Neu5Ac [7]. Not surprisingly, the affinity of Neu5Ac2en is
similar for all types of sialidases, including mammalian
ones. Improvements in potency and specificity were
sought by synthesizing a number of Neu5Ac2en analogues
but the most potent, a halogenated derivative (FANA),
had only a micromolar ki [8], and none of these analogues
showed antiviral activity in animals.
Post-1983 and the NA structure determination: 1st generation
compounds 
Further progress was only made when crystal structures of
influenza A NA [2,4,9] became available. The crystal
structure revealed a tetrameric ‘head’, with each subunit
possessing a b -sheet propeller structure and a surface
depression surrounded by conserved residues which
turned out to be the active site (Figure 3). von Itzstein et
al. [10,11] probed the active site computationally using
the GRID program [12,13] to detect energetically favour-
able binding sites for different functional groups. This
analysis revealed a conserved pocket in the NA–Neu5Ac
complex that could be filled by a basic substituent at the
4-OH position of Neu5Ac2en that would interact with
Glu119 and Glu227 (Figure 4a; region A). As a result of
this finding, 4-guanidino-Neu5Ac2en (GG167) was subse-
quently investigated and turned out to be very potent and
specific against influenza A and B; this compound is now
undergoing phase II clinical trials. Although resistant
strains have been isolated in tissue culture, none has so
far been identified in animals or in clinical trials. The
resistant strains have a single point mutation (Glu119fi
Gly) in the 4-OH pocket, which results in a NA that is
less stable than the parent NA but has the same specific
activity [14].
Crystal structures of the NA–4-guanidino-Neu5Ac2en
complex [10,15] confirmed that 4-guanidino-Neu5Ac2en
has the same binding mode as Neu5Ac2en and generally
validated the SBDD. A deviation from the initial
modelled structure was the orientation of the 4-guanidino
substituent, which whilst engaging in a salt link to Glu119,
did not form hydrogen bonds to it as designed.
Subsequent modelling of the complex using refined pro-
tocols yielded structures close to that observed experi-
mentally [15,16]. Moreover, from models of the complexes
of a series of 4-OH-substituted Neu5Ac2en analogues, a
correlation was obtained between experimental binding
affinities and relative electrostatic binding free energies
calculated using a continuum electrostatic model and
neglecting changes in internal ligand energy [17].
Neu5Ac analogues with substituents chosen to exploit
other favourable binding sites detected with the GRID
program have been synthesized. For example, 4-epi-amino-
Neu5Ac2en was designed to exploit region B in Figure 4a;
it bound NA tenfold more tightly than Neu5Ac2en but
tenfold less well than 4-amino-Neu5Ac2en, apparently
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Figure 1
Schematic diagram showing the chronology
of the main steps in the design of
antineuraminidase inhibitors. ki and IC50
values are given for the inhibition of
neuraminidase activity. Compounds GG167
and GS4104 are now in clinical trials.
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because it could only just fit into the binding site without
causing too much distortion [11]. Improved binding by
substituting a phosphonate instead of the carboxylate
moiety of Neu5Ac was predicted [11] and independently
shown to improve binding ten to 100-fold over that of
Neu5Ac [18]. The equatorial phosphonate analogue
appears to make more favourable interactions with the
protein and to bind with a less distorted ring than Neu5Ac.
Post-1983 and the NA structure determination: 2nd
generation compounds
GG167 must be inhaled or used as a nasal spray because
of its poor oral bioavailability and rapid excretion. Thus
further design studies have been aimed at deriving more
stable noncarbohydrate compounds. Attempts to replace
the pyranose ring of Neu5Ac2en with a flat benzene ring
have so far resulted in less potent inhibitors [19,20], 
indicating that the shape of the strained pyranose ring
and the orientation of the substituents on the ring may be
important for high affinity. Benzoic acid analogues have,
however, provided several interesting insights as regards
SBDD. In particular, a benzoic acid analogue (BANA113;
Figure 1) with a guanidino substituent designed to bind
in the same pocket as that of GG167 actually bound in a
different orientation with the guanidino group at the
position of the glycerol group of Neu5Ac2en (region D;
Figure 4a) [20]. Using the GRID program to locate sub-
stituents and the continuum electrostatics approach to
compute binding constants, Jedrzejas et al. [21] estimated
that the addition of a second guanidino group would
increase binding affinity. Subsequent experimental data
for a compound with two guanidino groups showed that it
bound structurally as anticipated [22]. The addition of 
a second guanidino group, however, did not increase
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Figure 2
Schematic diagram showing SBDD
approaches applied to the design of anti-
influenza agents. The routes by which the best
inhibitors have been derived are indicated:
those shown by black arrows have led to drug
candidates in clinical trials.
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binding affinity indicating that desolvation effects may
have been underestimated.
Recently, carbocyclic analogues that closely mimic the
ring structure of Neu5Ac2en were synthesized and found
to have antineuraminidase activity [23]. By making the
functional groups attached to the ring more lipophilic,
Kim et al. [1]. derived an orally bioavailable compound,
GS4104 (Figure 1), with potency exceeding that of GG167.
This compound has now entered clinical trials and has
shown activity against influenza A and B in animals. The
design rationale used for GS4104 is summarized in Figure
5 and was validated crystallographically [1]. The crystal
structure showed that the hydrophobic substituent intro-
duced to improve lipophilicity packed well with hydrocar-
bon sidechains but forced the carboxylate group of Glu276
to reorient away from the binding pocket.
Comparison of the design of anti-influenza agents targeted
at NA and HA
Both HA and NA bind sialic acid with affinities in the mil-
limolar range. The crystal structure of HA [24] was pub-
lished in 1981, shortly before that of NA, and shows a
trimeric ‘head-on-stalk’ structure with, like NA, sialyl-
binding sites in the ‘head’. Despite these parallels, when
similar design strategies to those employed for antineu-
raminidase inhibitors have been applied to HA, they have
so far met with less success and other strategies have been
employed to achieve potent inhibitors of haemagglutina-
tion. The reasons for these differences are discussed here.
Choice of binding site and ligand type: de novo versus native
HA is responsible for binding to cell receptors and for
membrane fusion. Bodian et al. [25] used the DOCK
program to identify a non-native binding site on the
protein and, by means of database screening, uncovered
promising lead compounds that stabilize the nonfusogenic
conformation of HA. On the other hand, most inhibitor
design against HA has been directed towards compounds
which block virus attachment to cell receptors by binding
in the highly conserved native Neu5Ac-binding site. As
yet, no novel potent inhibitors which bind to this site have
been reported as a result of de novo computer-aided
design, although potential inhibitors have been suggested
[26–28]. Instead, all reported inhibitors binding at the
Neu5Ac-binding site have incorporated analogues of the
native ligand. The native ligand, however, provides a
better starting point for inhibitor design for NA than 
HA for several reasons. Firstly, for NA, knowledge that
enzymes tend to bind transition state analogues tightly
could be used to derive a lead compound (Neu5Ac2en)
with reasonably high affinity. Its affinity is greater than
that of Neu5Ac because it is not internally strained 
when bound and because binding is not opposed by an
unfavourable anomeric ratio. (Both NA and HA bind the a
anomer of Neu5Ac which has only 5% population in solu-
tion.) Secondly, Neu5Ac binds NA in a distorted boat con-
formation [29–31], whereas it binds HA in an unstrained
chair conformation [32] and thus, as its binding affinities
to HA and NA are very similar, makes less favourable
interactions with HA. This can be understood from com-
paring the structures of the two complexes shown in
Figure 3. The binding site in HA is shallower and has
fewer charged residues. The functional groups on Neu5Ac
make different interactions in the two proteins and, in par-
ticular, the carboxylate group is equatorial in NA and sur-
rounded by three arginine residues while it is axial in HA,
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Figure 3
The sialyl-binding sites in the crystal structures of (a) NA complexed
with Neu5Ac and (b) HA complexed with sialyl lactose with only the
sialyl moiety shown. All residues with atoms within 5 Å of any atom in
the sialyl group are shown by van der Waals spheres coloured
according to residue polarity: red, acidic; blue, basic; yellow, polar;
white, nonpolar. The ligands are coloured according to atom type and
water molecules in the NA-binding site are shown by small red
spheres. Differences in the polarity and solvent-exposure of the NA
and HA-binding sites can be observed.
pointing into the binding site but lacking positively
charged protein residues in its immediate vicinity. Finally,
sialoside haemagglutination inhibitors must be designed
to be resistant to inactivation by NA. On the other hand, it
would be advantageous for NA inhibitors to bind to HA
and thus inhibit cell attachment.
Improving binding by substituent modification
Many Neu5Ac analogues have been investigated for inhi-
bition of haemagglutination [33,34], but the most potent
monovalent sialoside analogue inhibitor reported to date
has a KD of 3.7 m M for HA [35]. This is a fluorescent mol-
ecule which has a large dansyl group attached at the 4-OH
position by a flexible glycine linker. This position for the
fluorophore was chosen because the structure of NA
indicated that such a large group could not be accommo-
dated at the 4-OH position and indeed, no cleavage of the
glycosidic bonds by NA was observed. In contrast, in HA
the 4OH position is exposed to solution (Figure 3b) and
the dansyl moiety has been shown crystallographically to
point into solution [36].
For HA, an approximately 103-fold improvement in 
inhibition compared to the lead compound, Neu5Aca 2Me,
has been achieved by modifying substituents [35];
whereas for NA, the corresponding improvement com-
pared to Neu5Ac2en is 104–105 fold. An explanation for
this difference is provided by comparison of the GRID
energy maps for an amino probe (see Figure 4 legend). In
NA, the pocket for the 4-amino substituent is larger and
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Figure 4
The sialyl-binding sites of (a) NA and (b) HA.
The colouring scheme is the same as used in
Figure 3. The contours enclose energetically
favourable binding regions for an amino probe
computed with the GRID program (pink: –15;
cyan: –9 kcal/mol). The regions identified in
NA are: A, the most favourable region where
the guanidino group of GG167 binds [15]; B,
the region where the amino group of 4-epi-
amino-Neu5Ac2en is designed to bind [11];
C, a region whose exploitation in ligand
design has not yet been reported; D, the
region where the guanidino group of
BANA113 binds [19]. In HA, only one
energetically favourable region is observed at
these contour levels and is located near the 9-
OH group of Neu5Ac where hydrogen bonds
can be made to Glu190, Ser228 and Tyr98
[26]; this region was also detected by a
HOOK/MCSS computation [28]. In (b), 9-
amino-9-deoxy-Neu5Aca 2Me
(Neu5Aca 2Me9N) is shown in dark green at
its crystallographically observed position in its
complex with HA: the amino group is shifted
~0.8 Å out of the binding site from the
position of 9-OH [33] and lies less than 0.5 Å
from the position of the GRID energy
minimum for the amino probe. This energy
minimum is at about –12 kcal/mol, whereas
the closest energy minimum for a hydroxyl
probe is at about –9 kcal/mol and, therefore,
one might expect an amino substituted
compound to bind better than a hydroxylated
one. However, substitution of 9-OH of
Neu5Aca 2Me by an amino group resulted in
an eightfold reduced binding affinity [33]. A
reason for the reduced affinity, is that the
GRID energy minimum for the amino probe is
narrow with steep gradients. At the position of
9-NH3 in Neu5Aca 2Me9N, the GRID energy
for the amino probe, while more favourable
than for a hydroxyl probe, is 4 kcal/mol greater
than at the energy minimum despite its
proximity. At the position of 9-OH in
Neu5Aca 2Me, the relative GRID energies of
the two probes are inverted and the hydroxyl
group is favoured. Thus the GRID energy
maps are consistent with the experimental
observations at the 9-OH and 9-NH3
positions, but the precise position of the
energy minimum for the amino probe cannot
be attained by the 9-NH3 group in
Neu5Aca 2Me9N, probably because the
positions of its other functional groups cannot
be too unduly compromised. In contrast, the
4-OH binding pocket in NA has a large more
energetically favourable region that can be
utilized for improving binding more easily.
much more energetically favourable than that for an
amino substituent in HA. Thus the desolvation energy of
an amino group can be overcome more easily and exploit-
ation of the binding pocket is facilitated by its size, which
provides more flexibility for attaining complementarity
for other functional groups in the ligand.
Alternative strategy for HA: exploitation of polyvalency
HA binds sialosides with low affinity yet the influenza
virus binds tightly to cells. This high affinity is achieved by
the simultaneous binding of multiple HAs to sialoside cell
receptors which is possible because of the high density of
HA on the virion surface (~five times that of NA) and the
high density of Neu5Ac on the mammalian cell surface.
The same strategy has been exploited in influenza
inhibitor design resulting in a number of multivalent
sialoside-bearing inhibitors that are more potent than
monovalent ones (see [37] and references therein). Poly-
meric haemagglutination inhibitors based on liposomes,
poly(acrylic acid) or polyacrylamide, have reported  poten-
cies of up to ~10-11 M [37,38]. Potency is achieved in three
ways: by the use of C-glycosides because these, unlike the
natural O-glycosidic linkages, are resistant to cleavage by
NA; by high-affinity binding through the entropic advan-
tage of polyvalency; and by steric stabilization of the
surface preventing HA from binding the cell receptors.
Concluding remarks
The success of the SBDD of antineuraminidase agents is
very encouraging, showing that it is possible to improve
binding by modifying substituents on a known ligand using
structural information and computational techniques. The
studies on NA and HA both show the ability of computa-
tional techniques to locate binding sites in proteins for
functional groups, but point to short comings in the ability
to estimate ligand binding affinities and further work is nec-
essary to improve this. The successful approach against NA
was, nevertheless, rather conservative, that is based on a
transition-state analogue binding at a native binding site on
the protein. De novo design techniques for deriving novel
ligands, independently of known ligands, to bind to native
or non-native binding sites are much less reliable. Both
design strategies should benefit from recent advances in
combinatorial chemistry as the complementary ‘rational’
and ‘random’ approaches to SBDD become integrated.
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